Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer

NCT06507371 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

170

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer

Interventions

RADIATION: node-sparing modified short-course radiotherapy
DRUG: PD-1 antibody
DRUG: Capecitabine
DRUG: Oxaliplatin
RADIATION: standard short-course radiotherapy

Sponsor

Sir Run Run Shaw Hospital